Figure 2From: The clinical response to vemurafenib in a patient with a rare BRAF V600DK601delmutation-positive melanoma Primer extension and fragment analysis. Representative electropherograms of BRAF primer extension products, showing mutated and wild type controls (A), tumor DNA from a melanoma patient without a BRAF mutation (B) and the patient’s tumor DNA with a p.V600E mutation (C).Back to article page